Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme

Advice programme

Showing 351 to 375 of 403

TitleTypeExpected publication date
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Technology appraisal guidanceTBC
Targeted Muscle Reinnervation for refractory pain after limb amputationInterventional procedures guidance
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]Technology appraisal guidance
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401Technology appraisal guidanceTBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]Technology appraisal guidanceTBC
Technologies for the assessment of attention deficit hyperactivity disorder (ADHD)Diagnostics guidance
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]Technology appraisal guidanceTBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]Technology appraisal guidanceTBC
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition ID6259Technology appraisal guidanceTBC
Teprotumumab for treating thyroid eye disease ID6432Technology appraisal guidanceTBC
Third molars (impacted) - prophylactic removal [ID898]Technology appraisal guidanceTBC
Tirzepatide for managing overweight and obesity [ID6179]Technology appraisal guidance
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]Technology appraisal guidanceTBC
Tobacco: preventing uptake, promoting quitting and treating dependence - Cytisine for smoking cessationNICE guidelineTBC
Topical Antimicrobial dressings for wound care: Late stage assessmentHealth technology evaluation
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Total hip arthroplasty using the superpath approach for osteoarthritisInterventional procedures guidanceTBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]Technology appraisal guidanceTBC
Transcatheter aortic valve implantation for native aortic valve regurgitationInterventional procedures guidance
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessmentHealth technology evaluation
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidance
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All